Literature DB >> 1697907

Comparison of two host cell range variants of feline immunodeficiency virus.

T R Phillips1, R L Talbott, C Lamont, S Muir, K Lovelace, J H Elder.   

Abstract

Two molecular clones of feline immunodeficiency virus were compared. The first clone, 34TF10, was from a Petaluma, Calif., isolate; the second, PPR, was isolated from a cat in the San Diego, Calif., area. The cats from which the isolates were obtained suffered from chronic debilitating illnesses. The two molecular clones differed in their in vitro host cell range. The 34TF10 clone infected the Crandall feline kidney and G355-5 cell lines, but replicated less efficiently on feline peripheral blood leukocytes. In contrast, the PPR clone productively infected the primary feline peripheral blood leukocytes but not Crandall feline kidney or G355-5 cells. The 34TF10 and PPR clones had an overall sequence identity of 91%. The env gene was the least conserved (85% at the amino acid level). Additionally, the potential open reading frame for a Tat-like protein, ORF 2, contained a stop codon in the 34TF10 isolate which was not found in the PPR clone. This truncation did not prevent in vitro or in vivo replication of 34TF10. Two splice acceptor sites were identified in the 34TF10 clone. One was 5' to the beginning of the putative tat open reading frame, and the other was 5' to the putative vif product. Both of these acceptor sites were conserved in the PPR clone. The long terminal repeats of the viruses were 7% divergent between the two clones, with a lack of conservation in putative NF-kappa B, LBP-1, and CCAAT enhancer-promoter sites.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1697907      PMCID: PMC247944     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Induction of human interferon gene expression is associated with a nuclear factor that interacts with the NF-kappa B site of the human immunodeficiency virus enhancer.

Authors:  J Hiscott; D Alper; L Cohen; J F Leblanc; L Sportza; A Wong; S Xanthoudakis
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

2.  Analysis of the role of the transcription factor ATF in the assembly of a functional preinitiation complex.

Authors:  T W Hai; M Horikoshi; R G Roeder; M R Green
Journal:  Cell       Date:  1988-09-23       Impact factor: 41.582

3.  Fine structure genetic analysis of a beta-globin promoter.

Authors:  R M Myers; K Tilly; T Maniatis
Journal:  Science       Date:  1986-05-02       Impact factor: 47.728

Review 4.  Feline immunodeficiency virus infection.

Authors:  N C Pedersen; J K Yamamoto; T Ishida; H Hansen
Journal:  Vet Immunol Immunopathol       Date:  1989-05       Impact factor: 2.046

5.  Interaction of a common cellular transcription factor, ATF, with regulatory elements in both E1a- and cyclic AMP-inducible promoters.

Authors:  Y S Lin; M R Green
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

6.  Enhancer binding factors AP-4 and AP-1 act in concert to activate SV40 late transcription in vitro.

Authors:  N Mermod; T J Williams; R Tjian
Journal:  Nature       Date:  1988-04-07       Impact factor: 49.962

7.  Pathogenic and host range determinants of the feline aplastic anemia retrovirus.

Authors:  N Riedel; E A Hoover; R E Dornsife; J I Mullins
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

8.  The same inducible nuclear proteins regulates mitogen activation of both the interleukin-2 receptor-alpha gene and type 1 HIV.

Authors:  E Böhnlein; J W Lowenthal; M Siekevitz; D W Ballard; B R Franza; W C Greene
Journal:  Cell       Date:  1988-06-03       Impact factor: 41.582

9.  Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization.

Authors:  D D Ho; J C Kaplan; I E Rackauskas; M E Gurney
Journal:  Science       Date:  1988-02-26       Impact factor: 47.728

10.  Bovine leukemia virus trans-activator p38tax activates heterologous promoters with a common sequence known as a cAMP-responsive element or the binding site of a cellular transcription factor ATF.

Authors:  I Katoh; Y Yoshinaka; Y Ikawa
Journal:  EMBO J       Date:  1989-02       Impact factor: 11.598

View more
  110 in total

1.  Blocking of feline immunodeficiency virus infection by a monoclonal antibody to CD9 is via inhibition of virus release rather than interference with receptor binding.

Authors:  A de Parseval; D L Lerner; P Borrow; B J Willett; J H Elder
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag.

Authors:  P Sova; D J Volsky; L Wang; W Chao
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 3.  FIV and neuroAIDS.

Authors:  Howard S Fox; Tom R Phillips
Journal:  J Neurovirol       Date:  2002-06       Impact factor: 2.643

4.  Distinct subsets of retroviruses encode dUTPase.

Authors:  J H Elder; D L Lerner; C S Hasselkus-Light; D J Fontenot; E Hunter; P A Luciw; R C Montelaro; T R Phillips
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

5.  Specific interaction of feline immunodeficiency virus surface glycoprotein with human DC-SIGN.

Authors:  Aymeric de Parseval; Stephen V Su; John H Elder; Benhur Lee
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

6.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1991-01-11       Impact factor: 16.971

7.  A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity.

Authors:  S Lombardi; C Garzelli; M Pistello; C Massi; D Matteucci; F Baldinotti; G Cammarota; L da Prato; P Bandecchi; F Tozzini
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

8.  Feline immunodeficiency virus infection: plasma, but not peripheral blood mononuclear cell virus titer is influenced by zidovudine and cyclosporine.

Authors:  J Meers; G M del Fierro; R B Cope; H S Park; W K Greene; W F Robinson
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

9.  Neutralizing antibodies in cats infected with feline immunodeficiency virus.

Authors:  F Tozzini; D Matteucci; P Bandecchi; F Baldinotti; K Siebelink; A Osterhaus; M Bendinelli
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

10.  Phylogenetic analysis of the long terminal repeat of feline immunodeficiency viruses from Japan, Argentina and Australia.

Authors:  H Yamada; T Miyazawa; K Tomonaga; Y Kawaguchi; K Maeda; M C Castellano; C Kai; Y Tohya; T Mikami
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.